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Abstract
Genetic Analysis Workshop 16 (GAW16) Problem 2 presented data from the Framingham Heart
Study (FHS), an observational, prospective study of risk factors for cardiovascular disease begun in
1948. Data have been collected in three generations of family participants in the study and the data
presented for GAW16 included phenotype data from all three generations, with four examinations
of data collected repeatedly for the first two generations. The trait data consisted of information on
blood pressure, hypertension treatment, lipid levels, diabetes and blood glucose, smoking, alcohol
consumed, weight, and coronary heart disease incidence. Additionally, genotype data obtained
through a genome-wide scan (FHS SHARe) of 550,000 single-nucleotide polymorphisms from
Affymetrix chips were included with the GAW16 data. The genotype data were also used for
GAW16 Problem 3, where simulated phenotypes were generated using the actual FHS genotypes.
These data served to provide investigators with a rich resource to study the behavior of genome-
wide scans with longitudinally collected family data and to develop and apply new procedures
Introduction
The Framingham Heart Study (FHS) – under the
direction of National Heart, Lung, and Blood Institute
(NHLBI) – began in 1948 with the recruitment of adults
from the town of Framingham, Massachusetts. At the
time, little was known about the general causes of heart
disease and stroke, but death rates for cardiovascular
disease (CVD) had been increasing steadily since the
beginning of the 20th century and had become an
American epidemic. Even though rates of CVD have
declined in recent decades, it remains the primary cause
of death in both men and women in the US and in many
other parts of the world. The FHS is now conducted in
collaboration with Boston University.
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The objective of the FHS was to identify the common
factors or characteristics that contribute to CVD by
following its development over a long period of time in
a large group of population-based participants who had
not yet developed overt symptoms of CVD or suffered a
heart attack or stroke [1]. This project was unusually
ambitious. As one of the first population-based, epide-
miologic studies, it planned to follow participants
prospectively for 20 years with repeat examinations.
The NHLBI selected Framingham, Massachusetts because
it was a moderate-sized town with a relatively stable
population that was thought to reflect many commu-
nities in the US at that time. In the late 1940s an estimate
of the number of residents in the age range 30-60 years
who were eligible for recruitment was about 10,000
individuals. The study aimed to recruit approximately
6,000 participants. Between 1948 and 1953, the
researchers recruited 5,209 participants (2,336 men
and 2,873 women) between the ages of 29 and 62 and
began the first round of extensive physical examinations
and lifestyle interviews that they would later analyze for
common patterns related to CVD development. Partici-
pants were recruited from lists of addresses recorded for
the town census. Recruiters approached two out of every
three households for participation in the study. While
there was no intention to recruit families for family
studies, the plan was to recruit all household members
in the ages 30-60 within each house selected for study.
Hence, the Study recruited many related individuals,
including siblings, parent-child dyads, and 1,644 spouse
pairs. The investigators also thought that recruitment of
spouse pairs would encourage continued participation
for the original 20-year planned duration for the study.
Since 1948, these participants have returned to the study
every 2 years for a detailed medical history, physical
examination, and laboratory tests. Now at more than 60
years of follow up, there remain fewer than 500
participants from this cohort, known as the Original
Cohort.
Between 1971 and 1975 the Study enrolled a second-
generation group – 5,124 of the original participants’
children and the spouses of these children – to
participate in similar examinations. An important goal
in recruiting this Offspring Cohort was to evaluate the
heritable factors involved in the development of CVD
and its risk factors. Thus, the main strategy was to recruit
offspring where both parents participated in the Original
Cohort and those with one parent at higher risk of CVD
due to higher lipid levels. Of those recruited, 2,616
participants are offspring of the original spouse pairs and
34 are stepchildren. Another 898 offspring are children
of cohort members where only one parent was a study
participant and 1,576 are spouses of the offspring. The
Offspring Cohort participants have returned every 4
years through 2001 (except between Exams 1 and 2,
which had an intervening 8 years) for follow-up exams,
using protocols similar to those used for study of the
Original Cohort.
Between 2002 and 2005 the Study enrolled the third
generation (Generation 3) into the FHS - 4,095 offspring
of the second generation. None of their spouses were
recruited. At this time, the FHS also recruited an
additional 103 parents of this third generation who
were not recruited between 1971 and 1975. Data on the
latter group are not included in the GAW16 data. With
the recruitment of this third generation, the Study has
increasingly focused on genetic factors associated with
the development of CVD and its associated risk factors.
The Generation 3 Cohort is now participating in its
second examination. A description of the recruitment of
this third generation and comparison with the earlier
generations at their initial recruitment is presented in
Splansky et al. [2].
We owe a great deal of gratitude to the Framingham
participants for this rich resource of data that has accrued
over 60 years in three generations. It is their unflagging
commitment to the Study that makes our research
possible. Further information on the Study can be
found at the Framingham Heart Study web site [3].
Genotype data
In-depth genetic studies did not begin in the FHS until
the 1990s. In the late 1980s, family structures were
formally formed into extended pedigrees. Also in the late
1980s and through the 1990s, investigators extracted
DNA from blood samples of surviving FHS participants.
Because many Original Cohort members had died by
this time, study investigators obtained DNA samples
from less than 30% of this cohort. In the mid-1990s into
the early 2000s, the NHLBI Mammalian Genotyping
Service, Center for Medical Genetics genotyped genome-
wide microsatellites over several phases in the largest
330 families in the Study. And in the early 2000s, a 100 k
Affymetrix genome-wide scan was conducted in these
families [4]. In 2007, the FHS entered a new phase with
the establishment of the FHS SHARe (SNP Health
Association Resource) project by NHLBI and Boston
University, for which Affymetrix performed dense SNP
genotyping using approximately 550,000 SNPs (Gene-
Chip® Human Mapping 500 k Array Set and the 50 k
Human Gene Focused Panel) in 10,775 samples (some
duplicates) from the three generations of participants
(including over 900 pedigrees). The genotyping plat-
forms for the FHS SHARe project were the 250 k Sty, the
250 k Nsp, and the supplemental gene-centric 50 k chip.
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The Study obtained DNA for 89% of the participants
during the 1990s. To maximize the power of the study,
we also extracted DNA from 1,133 blood samples, drawn
from participants who had no available DNA samples, to
include in the SHARe project. These samples had been
sitting in our freezers for some time, a few as far back as
the 1970s. We refer to these DNA samples as the legacy
samples. These samples had a higher failure rate in the
genotyping process (40%) than the other 89% (3%). As
a result, to maximize the number of subjects included we
used different criteria for a sample to succeed in
genotyping for these two types of DNA samples. All
non-legacy samples must succeed on all three platforms,
while legacy samples needed to pass on at least one
platform. When a sample failed, additional attempts
were made. Samples that repeatedly failed two to four
times were called failures. Other samples failed due to
issues of genotyped sex identification not matching our
records, low SNP concordance among SNPs common
across arrays, or contamination. Eighty-nine percent of
the legacy samples for which genotyping results are
available passed all three platforms. The genotyping data
for the 10,043 samples from 9,354 participants that
passed the Affymetrix criteria were additionally checked
for sex consistency and consistency with family structure,
resulting in genotyping data for 9,274 participants in
FHS SHARe. Genotype calls were made with the BRLMM
algorithm.
The National Center for Biotechnology Information
database of Genotypes and Phenotypes [5] houses the
SHARe database containing all ~550,000 SNPs and
extensive phenotype data. This genome-wide dense
SNP scan and a subset of phenotypes from the FHS
were the focus of the Genetic Analysis Workshop 16.
These same genotypes were also used to simulate the
phenotype data for GAW16 Problem 3 [6]. Recently, up
to ~2.5 M imputed SNPs have been added to dbGaP, but
these genotypes were not available for the GAW16.
Data for Genetic Analysis Workshop 16
The FHS data sets for Genetic Analysis Workshop 16
include pedigree, genotype, and phenotype data. The
phenotypic data provide information on those partici-
pants who have consented to anyone’s use, including
those at for-profit and not-for-profit institutions. The
pedigree file contains all biologically related participants
in the FHS and is not limited to the 7,230 participants
with full consent. A total of 7,130 participants have
phenotype data: 373 Original Cohort, 2,760 Offspring
Cohort, and 3,997 Generation 3 participants. No
phenotypes were included from the 100 fully consenting
non-offspring spouses. Of the 7,230 consenting partici-
pants, 6,979 are members of pedigrees and 251 are
unrelated. Overall, there are a total of 6,848 participants
who are genotyped, including 6,621 in pedigrees and
227 unrelated participants. There are 766 pedigrees with
2 to 301 genotyped participants: 134 pedigrees with 2,
123 with 3, 98 with 4, 85 with 5, 177 with 6 to 10,
72 with 11 to 15, 30 with 16 to 20, and 47 with more
than 20.
We selected data from a subset of examinations for
Genetic Analysis Workshop 16: Exams 1 (1948-1953), 4
(1954-1958), 7 (1960-1964), and 11 (1968-1971) for
the Original Cohort; Exams 1 (1971-1975), 3 (1983-
1987), 5 (1991-1995), and 7 (1998-2001) for the
Offspring Cohort; and Exam 1 for the Generation 3
Cohort. We chose these exams so that data from FHS
participants of approximately the same age from the
three cohorts were considered. Only one exam had been
completed for Generation 3 and so only data from one
exam were available for these participants. Age, sex, and
descriptive statistics for these participants are provided in
Table 1. Note that Original Cohort participants with data
included only the select few who survived ~40 years to
have DNA collected and to provide consent for the
SHARe project.
Genotype data sets contained ~550,000 genotypes for
each participant. We cleaned genotype data for familial
relationships. We evaluated whether the genotypes of
participants were consistent with their reported familial
relationships. We used PREST [7] and sib-kin from Aspex
[8] to perform this analysis within families [9].
Additionally, we checked for unknown (cryptic) first-
degree relationships between families using PLINK
[10,11]. In some cases, we altered familial relationships
as a result. Such errors could occur from unknown
familial relationships or sample mix-up. Cleaning at this
Table 1: Age and sex of Framingham Heart Study participants
for GAW16 by cohort and exam
Variable Original
Cohort
Offspring
Cohort
Generation
3 Cohort
Recruited sample size 5209 5124 4095
Number with 550 k
genotype data
1529 3753 3893
Sample size for GAW16 373 2760 3997
Sample size for GAW16 with
genotypes
357 2584 3811
Ages (Mean ± SD)
Exam 1 34.9 ± 3.9 33.7 ± 9.3 40.2 ± 8.8
Exam 4 (Original),
Exam 3 (Offspring)
40.9 ± 3.9 46.3 ± 9.3 NA
Exam 7 (Original),
Exam 5 (Offspring)
47.0 ± 3.9 53.3 ± 9.2 NA
Exam 11 (Original),
Exam 7 (Offspring)
54.7 ± 3.8 60.2 ± 9.1 NA
% Female, Exam 1 69.2% 54.4% 53.3%
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stage could result in all genotypes of some individuals
being deleted. The genotype data set included legacy
DNA samples, which were of poorer quality with a
higher rate of missing genotypes. Files with allele
intensities and confidence scores for each marker and .
cel files were also available at dbGaP [5].
The family structure file, defining the pedigree structures,
was provided. This file also included indicators for which
cohort a participant belongs to and whether the
participant is genotyped or phenotyped. There were
8,732 participants in this file who have been genotyped.
However, only data for those participants who consented
to general use (both for-profit and not-for-profit) were
available to GAW16.
Participants with phenotype data who are not in the
family file were not members of families and were
biologically unrelated to one another.
Three phenotype files are provided: 1) Original Cohort
participants, 2) Offspring Cohort participants, 3) Gen-
eration 3 Cohort participants. These files provide
information on demographics (sex and age), height,
weight, traditional risk factors for coronary heart disease
(blood pressure and hypertension, diabetes and blood
glucose, smoking, alcohol, and lipid levels), and on
incident coronary heart disease and age at onset. Also
included are age at onset of diabetes, age at death, and
age at last contact. These participants were followed up
for events through 2006.
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